{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T15:20:42Z","timestamp":1790436042587,"version":"4.1.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2016,11,11]],"date-time":"2016-11-11T00:00:00Z","timestamp":1478822400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1038\/leu.2016.314","type":"journal-article","created":{"date-parts":[[2016,11,11]],"date-time":"2016-11-11T02:46:57Z","timestamp":1478832417000},"page":"1187-1195","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML"],"prefix":"10.1038","volume":"31","author":[{"given":"D","family":"Malani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Murum\u00e4gi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Kontro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Eldfors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Karjalainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M M","family":"Majumder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Ojamies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Pemovska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Wennerberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Heckman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Porkka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Aittokallio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O","family":"Kallioniemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,11,11]]},"reference":[{"key":"BFleu2016314_CR1","doi-asserted-by":"publisher","first-page":"5012","DOI":"10.1002\/cncr.25263","volume":"116","author":"JM Rowe","year":"2010","unstructured":"Rowe JM, Kim HT, Cassileth PA, Lazarus HM, Litzow MR, Wiernik PH et al. Adult patients with acute myeloid leukemia who achieve complete remission after 1 or 2 cycles of induction have a similar prognosis. Cancer 2010; 116: 5012\u20135021.","journal-title":"Cancer"},{"key":"BFleu2016314_CR2","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1080\/1042819032000159861","volume":"45","author":"E Cros","year":"2004","unstructured":"Cros E, Jordheim L, Dumontet C, Galmarini CM . Problems related to resistance to cytarabine in acute myeloid leukemia. Leuk Lymphoma 2004; 45: 1123\u20131132.","journal-title":"Leuk Lymphoma"},{"key":"BFleu2016314_CR3","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1182\/blood-2005-01-0178","volume":"106","author":"MS Tallman","year":"2005","unstructured":"Tallman MS, Gilliland DG, Rowe JM . Drug therapy for acute myeloid leukemia. Blood 2005; 106: 1154\u20131163.","journal-title":"Blood"},{"key":"BFleu2016314_CR4","first-page":"396","volume":"2009","author":"JM Rowe","year":"2009","unstructured":"Rowe JM . Optimal induction and post-remission therapy for AML in first remission. ASH Education Program Book 2009; 2009: 396\u2013405.","journal-title":"ASH Education Program Book"},{"key":"BFleu2016314_CR5","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/hon.2191","volume":"34","author":"O Wolach","year":"2015","unstructured":"Wolach O, Itchaki G, Bar-Natan M, Yeshurun M, Ram R, Herscovici C et al. High-dose cytarabine as salvage therapy for relapsed or refractory acute myeloid leukemia-is more better or more of the same? Hematol Oncol 2015; 34: 28\u201335.","journal-title":"Hematol Oncol"},{"key":"BFleu2016314_CR6","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1046\/j.1365-2141.2001.02756.x","volume":"113","author":"JP Matthews","year":"2001","unstructured":"Matthews JP, Bishop JF, Young GAR, Juneja SK, Lowenthal RM, Garson OM et al. Patterns of failure with increasing intensification of induction chemotherapy for acute myeloid leukaemia. Br J Haematol 2001; 113: 727\u2013736.","journal-title":"Br J Haematol"},{"key":"BFleu2016314_CR7","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1158\/0008-5472.CAN-07-5528","volume":"68","author":"J Cai","year":"2008","unstructured":"Cai J, Damaraju VL, Groulx N, Mowles D, Peng Y, Robins MJ et al. Two distinct molecular mechanisms underlying cytarabine resistance in human leukemic cells. Cancer Res 2008; 68: 2349\u20132357.","journal-title":"Cancer Res"},{"key":"BFleu2016314_CR8","doi-asserted-by":"publisher","first-page":"4598","DOI":"10.1186\/1476-4598-13-159","volume":"13","author":"M Klanova","year":"2014","unstructured":"Klanova M, Lorkova L, Vit O, Maswabi B, Molinsky J, Pospisilova J et al. Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents. Mol Cancer 2014; 13: 4598\u201313-159.","journal-title":"Mol Cancer"},{"key":"BFleu2016314_CR9","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1038\/leu.2010.88","volume":"24","author":"SK Rathe","year":"2010","unstructured":"Rathe SK, Largaespada DA . Deoxycytidine kinase is downregulated in Ara-C-resistant acute myeloid leukemia murine cell lines. Leukemia 2010; 24: 1513\u20131515.","journal-title":"Leukemia"},{"key":"BFleu2016314_CR10","doi-asserted-by":"publisher","first-page":"32,43.e1","DOI":"10.1016\/j.exphem.2014.09.007","volume":"43","author":"D Nowak","year":"2015","unstructured":"Nowak D, Liem NL, Mossner M, Klaumunzer M, Papa RA, Nowak V et al. Variegated clonality and rapid emergence of new molecular lesions in xenografts of acute lymphoblastic leukemia are associated with drug resistance. Exp Hematol 2015; 43: 32,43.e1\u201335.","journal-title":"Exp Hematol"},{"key":"BFleu2016314_CR11","doi-asserted-by":"publisher","first-page":"6048","DOI":"10.1038\/srep06048","volume":"4","author":"SK Rathe","year":"2014","unstructured":"Rathe SK, Moriarity BS, Stoltenberg CB, Kurata M, Aumann NK, Rahrmann EP et al. Using RNA-seq and targeted nucleases to identify mechanisms of drug resistance in acute myeloid leukemia. Sci Rep 2014; 4: 6048.","journal-title":"Sci Rep"},{"key":"BFleu2016314_CR12","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/S0145-2126(01)00184-9","volume":"26","author":"CM Galmarini","year":"2002","unstructured":"Galmarini CM, Thomas X, Calvo F, Rousselot P, Jafaari AE, Cros E et al. Potential mechanisms of resistance to cytarabine in AML patients. Leuk Res 2002; 26: 621\u2013629.","journal-title":"Leuk Res"},{"key":"BFleu2016314_CR13","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1038\/sj.leu.2403977","volume":"19","author":"W Bardenheuer","year":"2005","unstructured":"Bardenheuer W, Lehmberg K, Rattmann I, Brueckner A, Schneider A, Sorg UR et al. Resistance to cytarabine and gemcitabine and in vitro selection of transduced cells after retroviral expression of cytidine deaminase in human hematopoietic progenitor cells. Leukemia 2005; 19: 2281\u20132288.","journal-title":"Leukemia"},{"key":"BFleu2016314_CR14","doi-asserted-by":"publisher","first-page":"877","DOI":"10.2217\/pgs.15.44","volume":"16","author":"A Abraham","year":"2015","unstructured":"Abraham A, Varatharajan S, Karathedath S, Philip C, Lakshmi KM, Jayavelu AK et al. RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia. Pharmacogenomics 2015; 16: 877\u2013890.","journal-title":"Pharmacogenomics"},{"key":"BFleu2016314_CR15","first-page":"131","volume":"9","author":"FJ Keith","year":"1995","unstructured":"Keith FJ, Bradbury DA, Zhu YM, Russell NH . Inhibition of bcl-2 with antisense oligonucleotides induces apoptosis and increases the sensitivity of AML blasts to Ara-C. Leukemia 1995; 9: 131\u2013138.","journal-title":"Leukemia"},{"key":"BFleu2016314_CR16","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/ajh.10453","volume":"75","author":"A Saxena","year":"2004","unstructured":"Saxena A, Viswanathan S, Moshynska O, Tandon P, Sankaran K, Sheridan DP . Mcl-1 and Bcl-2\/Bax ratio are associated with treatment response but not with Rai stage in B-cell chronic lymphocytic leukemia. Am J Hematol 2004; 75: 22\u201333.","journal-title":"Am J Hematol"},{"key":"BFleu2016314_CR17","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1593\/neo.08972","volume":"10","author":"H Ogbomo","year":"2008","unstructured":"Ogbomo H, Michaelis M, Klassert D, Doerr HW, Cinatl J Jr . Resistance to cytarabine induces the up-regulation of nkg2d ligands and enhances natural killer cell lysis of leukemic cells. Neoplasia 2008; 10: 1402\u20131410.","journal-title":"Neoplasia"},{"key":"BFleu2016314_CR18","first-page":"1083","volume":"9","author":"D Steinbach","year":"2003","unstructured":"Steinbach D, Lengemann J, Voigt A, Hermann J, Zintl F, Sauerbrey A . Response to chemotherapy and expression of the genes encoding the multidrug resistance-associated proteins MRP2, MRP3, MRP4, MRP5, and SMRP in childhood acute myeloid leukemia. Clin Cancer Res 2003; 9: 1083\u20131086.","journal-title":"Clin Cancer Res"},{"key":"BFleu2016314_CR19","first-page":"911","volume":"38","author":"E Negoro","year":"2011","unstructured":"Negoro E, Yamauchi T, Urasaki Y, Nishi R, Hori H, Ueda T . Characterization of cytarabine-resistant leukemic cell lines established from five different blood cell lineages using gene expression and proteomic analyses. Int J Oncol 2011; 38: 911\u2013919.","journal-title":"Int J Oncol"},{"key":"BFleu2016314_CR20","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1182\/blood-2004-05-1933","volume":"105","author":"S Faderl","year":"2004","unstructured":"Faderl S, Gandhi V, O'Brien S, Bonate P, Cortes J, Estey E et al. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood 2004; 105: 940\u2013947.","journal-title":"Blood"},{"key":"BFleu2016314_CR21","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/nature13283","volume":"511","author":"HA Zahreddine","year":"2014","unstructured":"Zahreddine HA, Culjkovic-Kraljacic B, Assouline S, Gendron P, Romeo AA, Morris SJ et al. The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation. Nature 2014; 511: 90\u201393.","journal-title":"Nature"},{"key":"BFleu2016314_CR22","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1111\/j.1349-7006.2009.01111.x","volume":"100","author":"M Kobune","year":"2009","unstructured":"Kobune M, Takimoto R, Murase K, Iyama S, Sato T, Kikuchi S et al. Drug resistance is dramatically restored by hedgehog inhibitors in CD34+ leukemic cells. Cancer Sci 2009; 100: 948\u2013955.","journal-title":"Cancer Sci"},{"key":"BFleu2016314_CR23","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.molonc.2014.09.008","volume":"9","author":"C Xie","year":"2015","unstructured":"Xie C, Edwards H, Caldwell JT, Wang G, Taub JW, Ge Y . Obatoclax potentiates the cytotoxic effect of cytarabine on acute myeloid leukemia cells by enhancing DNA damage. Mol Oncol 2015; 9: 409\u2013421.","journal-title":"Mol Oncol"},{"key":"BFleu2016314_CR24","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1111\/cas.12103","volume":"104","author":"R Nishi","year":"2013","unstructured":"Nishi R, Yamauchi T, Negoro E, Takemura H, Ueda T . Combination of guanine arabinoside and Bcl-2 inhibitor YC137 overcomes the cytarabine resistance in HL-60 leukemia cell line. Cancer Sci 2013; 104: 502\u2013507.","journal-title":"Cancer Sci"},{"key":"BFleu2016314_CR25","doi-asserted-by":"publisher","first-page":"5193","DOI":"10.1038\/srep05193","volume":"4","author":"B Yadav","year":"2014","unstructured":"Yadav B, Pemovska T, Szwajda A, Kulesskiy E, Kontro M, Karjalainen R et al. Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies. Sci Rep 2014; 4: 5193.","journal-title":"Sci Rep"},{"key":"BFleu2016314_CR26","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1158\/2159-8290.CD-13-0350","volume":"3","author":"T Pemovska","year":"2013","unstructured":"Pemovska T, Kontro M, Yadav B, Edgren H, Eldfors S, Szwajda A et al. Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. Cancer Discov 2013; 3: 1416\u20131429.","journal-title":"Cancer Discov"},{"key":"BFleu2016314_CR27","doi-asserted-by":"publisher","first-page":"R94,2011","DOI":"10.1186\/gb-2011-12-9-r94","volume":"12","author":"AM Sulonen","year":"2011","unstructured":"Sulonen AM, Ellonen P, Almusa H, Lepisto M, Eldfors S, Hannula S et al. Comparison of solution-based exome capture methods for next generation sequencing. Genome Biol 2011; 12: R94,2011\u201312-9-r94.","journal-title":"Genome Biol"},{"key":"BFleu2016314_CR28","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1002\/humu.22033","volume":"33","author":"KV Fuentes Fajardo","year":"2012","unstructured":"Fuentes Fajardo KV, Adams D, NISC Comparative Sequencing Program Mason CE, Sincan M, Tifft C et al. Detecting false-positive signals in exome sequencing. Hum Mutat 2012; 33: 609\u2013613.","journal-title":"Hum Mutat"},{"key":"BFleu2016314_CR29","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1242\/dmm.021105","volume":"8","author":"B Yadav","year":"2015","unstructured":"Yadav B, Gopalacharyulu P, Pemovska T, Khan SA, Szwajda A, Tang J et al. From drug response profiling to target addiction scoring in cancer cell models. Dis Model Mech 2015; 8: 1255\u20131264.","journal-title":"Dis Model Mech"},{"key":"BFleu2016314_CR30","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1021\/ci400709d","volume":"54","author":"J Tang","year":"2014","unstructured":"Tang J, Szwajda A, Shakyawar S, Xu T, Hintsanen P, Wennerberg K et al. Making sense of large-scale kinase inhibitor bioactivity data sets: a comparative and integrative analysis. J Chem Inf Model 2014; 54: 735\u2013743.","journal-title":"J Chem Inf Model"},{"key":"BFleu2016314_CR31","doi-asserted-by":"publisher","first-page":"3589","DOI":"10.1182\/blood.V97.11.3589","volume":"97","author":"DL Stirewalt","year":"2001","unstructured":"Stirewalt DL, Kopecky KJ, Meshinchi S, Appelbaum FR, Slovak ML, Willman CL et al. FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood 2001; 97: 3589\u20133595.","journal-title":"Blood"},{"key":"BFleu2016314_CR32","doi-asserted-by":"crossref","unstructured":"The Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013; 368: 2059\u20132074.","DOI":"10.1056\/NEJMoa1301689"},{"key":"BFleu2016314_CR33","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1002\/(SICI)1096-911X(199608)27:2<114::AID-MPO8>3.0.CO;2-I","volume":"27","author":"GJL Kaspers","year":"1996","unstructured":"Kaspers GJL, Veerman AJP, Popp-Snijders C, Lomecky M, Van Zantwijk CH, Swinkels LMJW et al. Comparison of the antileukemic activity in vitro of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. Med Pediatr Oncol 1996; 27: 114\u2013121.","journal-title":"Med Pediatr Oncol"},{"key":"BFleu2016314_CR34","first-page":"1681","volume":"8","author":"S Greenstein","year":"2002","unstructured":"Greenstein S, Ghias K, Krett NL, Rosen ST . Mechanisms of glucocorticoid-mediated apoptosis in hematological malignancies. Clin Cancer Res 2002; 8: 1681\u20131694.","journal-title":"Clin Cancer Res"},{"key":"BFleu2016314_CR35","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/sj.leu.2402733","volume":"17","author":"WJE Tissing","year":"2003","unstructured":"Tissing WJE, Meijerink JPP, den Boer ML, Pieters R . Molecular determinants of glucocorticoid sensitivity and resistance in acute lymphoblastic leukemia. Leukemia 2003; 17: 17\u201325.","journal-title":"Leukemia"},{"key":"BFleu2016314_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00043426-199502000-00001","volume":"17","author":"PS Gaynon","year":"1995","unstructured":"Gaynon PS, Lustig RH . The use of glucocorticoids in acute lymphoblastic leukemia of childhood. Molecular, cellular, and clinical considerations. J Pediatr Hematol Oncol 1995; 17: 1\u201312.","journal-title":"J Pediatr Hematol Oncol"},{"key":"BFleu2016314_CR37","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S0145-2126(96)00089-6","volume":"21","author":"H Miyoshi","year":"1997","unstructured":"Miyoshi H, Ohki M, Nakagawa T, Honma Y . Glucocorticoids induce apoptosis in acute myeloid leukemia cell lines with a t(8;21) chromosome translocation. Leuk Res 1997; 21: 45\u201350.","journal-title":"Leuk Res"},{"key":"BFleu2016314_CR38","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1002\/(SICI)1096-8652(199904)60:4<255::AID-AJH1>3.0.CO;2-S","volume":"60","author":"N Ozbek","year":"1999","unstructured":"Ozbek N, Erdemli E, Hicsonmez G, Okur H, Tekelioglu M . Effects of methylprednisolone on human myeloid leukemic cells in vitro. Am J Hematol 1999; 60: 255\u2013259.","journal-title":"Am J Hematol"},{"key":"BFleu2016314_CR39","doi-asserted-by":"publisher","first-page":"573","DOI":"10.3109\/10428199909058462","volume":"33","author":"G Hicsonmez","year":"1999","unstructured":"Hicsonmez G, Tuncer M, Toksoy HB, Yenicesu I, Cetin M . Differentiation of leukemic cells induced by short-course high-dose methylprednisolone in children with different subtypes of acute myeloblastic leukemia. Leuk Lymphoma 1999; 33: 573\u2013580.","journal-title":"Leuk Lymphoma"},{"key":"BFleu2016314_CR40","first-page":"708","volume":"6","author":"FS Morrison","year":"1992","unstructured":"Morrison FS, Kopecky KJ, Head DR, Athens JW, Balcerzak SP, Gumbart C et al. Late intensification with POMP chemotherapy prolongs survival in acute myelogenous leukemia\u2014results of a Southwest Oncology Group study of rubidazone versus adriamycin for remission induction, prophylactic intrathecal therapy, late intensification, and levamisole maintenance. Leukemia 1992; 6: 708\u2013714.","journal-title":"Leukemia"},{"key":"BFleu2016314_CR41","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/BF00686107","volume":"34","author":"E Nagura","year":"1994","unstructured":"Nagura E, Kimura K, Yamada K, Ohta K, Maekawa T, Takaku F et al. Nationwide randomized comparative study of daunorubicin and aclarubicin in combination with behenoyl cytosine arabinoside, 6-mercaptopurine, and prednisolone for previously untreated acute myeloid leukemia. Cancer Chemother Pharmacol 1994; 34: 23\u201329.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BFleu2016314_CR42","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1038\/sj.leu.2403097","volume":"17","author":"EA Kolb","year":"2003","unstructured":"Kolb EA, Steinherz PG . A new multidrug reinduction protocol with topotecan, vinorelbine, thiotepa, dexamethasone, and gemcitabine for relapsed or refractory acute leukemia. Leukemia 2003; 17: 1967\u20131972.","journal-title":"Leukemia"},{"key":"BFleu2016314_CR43","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1007\/s000660050027","volume":"175","author":"M Mariotta","year":"1999","unstructured":"Mariotta M, Perewusnnyk G, Koechli OR, Little JB, von KD, Mirimanoff R et al. Dexamethasone-induced enhancement of resistance to ionizing radiation and chemotherapeutic agents in human tumor cells. Strahlentherapie und Onkologie 1999; 175: 392\u2013396.","journal-title":"Strahlentherapie und Onkologie"},{"key":"BFleu2016314_CR44","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1038\/sj.onc.1202071","volume":"17","author":"U Naumann","year":"1998","unstructured":"Naumann U, Durka S, Weller M . Dexamethasone-mediated protection from drug cytotoxicity: association with p21WAF1\/CIP1 protein accumulation? Oncogene 1998; 17: 1567\u20131575.","journal-title":"Oncogene"},{"key":"BFleu2016314_CR45","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.bbrc.2008.01.146","volume":"368","author":"A Asadi","year":"2008","unstructured":"Asadi A, Hedman E, Widen C, Zilliacus J, Gustafsson JA, Wikstrom AC . FMS-like tyrosine kinase 3 interacts with the glucocorticoid receptor complex and affects glucocorticoid dependent signaling. Biochem Biophys Res Commun 2008; 368: 569\u2013574.","journal-title":"Biochem Biophys Res Commun"},{"key":"BFleu2016314_CR46","first-page":"1165","volume":"34","author":"JH Song","year":"2009","unstructured":"Song JH, Kim SH, Kweon SH, Lee TH, Kim HJ, Kim HJ et al. Defective expression of deoxycytidine kinase in cytarabine-resistant acute myeloid leukemia cells. Int J Oncol 2009; 34: 1165\u20131171.","journal-title":"Int J Oncol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/leu2016314.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/leu2016314","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/leu.2016.314","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/leu2016314.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T14:06:22Z","timestamp":1684418782000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2016314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,11]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["BFleu2016314"],"URL":"https:\/\/doi.org\/10.1038\/leu.2016.314","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,11]]},"assertion":[{"value":"4 April 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}